Prognostic utility of various multidimensional grading scales among Saudi patients with bronchiectasis - 06/12/21
, Majed AL-Ghamdi a, b, c, Abdelmonim Abdulrahman a, b, c, Mohammad Khan a, b, c, Sulaiman AL-Rajhi a, c, d, Hamdan AL-Jahdali a, b, cBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 3 |
| Video | 0 |
| Altro | 0 |
Abstract |
Introduction |
A number of multidimensional scoring systems, including the Bronchiectasis Severity Index (BSI), the FACED score, and the Exacerbation-FACED (Exa-FACED, a derivative of FACED), have been proposed and validated to assess the severity and prognosis in patients with bronchiectasis. Although these metrics have been validated through large multicenter efforts in Europe and Latin America, there have been no attempts at external validation in other populations.
Ojectives |
The aim of this study was to validate specific multidimensional grading scales (BSI, FACED, and Exa-FACED) in predicting mortality, future exacerbations, and hospitalizations among Saudi patients with bronchiectasis.
Methods |
A prospective observational cohort study was conducted at a tertiary care centre. The three multidimensional grading scales (BSI, FACED, and Exa-FACED) were calculated for each patient. Future frequent acute exacerbations (≥2/year) and severe acute exacerbations leading to hospitalization were recorded for 1 year, and all-cause mortality was monitored for up to 5 years.
Results |
A total of 301 patients with bronchiectasis (mean age of 60±17 years and 66% female) were include. All Grading scales performed well in predicting 5-year survival. Area under the curve (AUC) values for BSI (0.86, 95% CI: 0.82–0.90), FACED (0.81, 95% CI: 0.76–0.85), and Ex-FACED (0.83, 95% CI: 0.78–0.87). The BSI (AUC=0.98, 95% CI: 0.96–0.99) performed better than FACED scoring (AUC=0.77, 95% CI: 0.71–0.81; P<0.0001) in predicting hospitalization. Exa-FACED scoring (AUC=0.84, 95% CI: 0.80–0.88) improved upon FACED scores in predicting hospitalization. The BSI (AUC=0.95, 95% CI: 0.91–0.97) fared significantly better than FACED scoring (AUC=0.76, 95% CI: 0.70–0.80; p<0.0001) in predicting frequent acute exacerbations (≥2/year). Again, Exa-FACED scoring (AUC=0.85, 95% CI: 0.81–0.89) improved upon FACED scores in predicting frequent acute exacerbations (≥2/year).
Conclusions |
All scoring systems performed adequately in 5-year mortality projections. Although Exa-FACED scoring improved upon FACED scores in predicting forthcoming frequent acute exacerbations and hospitalization, the BSI outperformed both in this regard.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Bronchiectasis, Bronchiectasis Severity Index (BSI), FACED score, Acute exacerbation, Hospitalization, Exacerbation-FACED (Exa-FACED)
Mappa
Vol 80
Articolo 100843- novembre 2021 Ritorno al numero
Articolo precedente
- Covid-19 severe hypoxemic pneumonia: A clinical experience using high-flow nasal oxygen therapy as first-line management
- G. Beduneau, D. Boyer, P.-G. Guitard, P. Gouin, D. Carpentier, S. Grangé, B. Veber, C. Girault, F. Tamion
- Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol
- Sarah Sannicolo, Matteo Giaj Levra, Audrey Le Gouellec, Caroline Aspord, Julien Boccard, Laurence Chaperot, Bertrand Toussaint, Denis Moro-sibilot, Dalil Hannani, Anne-Claire Toffart
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?